On Monday, Regenxbio Inc (NASDAQ: RGNX) opened lower -5.21% from the last session, before settling in for the closing price of $6.34. Price fluctuations for RGNX have ranged from $5.62 to $24.26 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 111.76% annually for the last half of the decade. Company’s average yearly earnings per share was noted 21.49% at the time writing. With a float of $44.72 million, this company’s outstanding shares have now reached $49.53 million.
In an organization with 344 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 39.46%, operating margin of -289.09%, and the pretax margin is -283.37%.
Regenxbio Inc (RGNX) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Regenxbio Inc is 9.75%, while institutional ownership is 87.23%. The most recent insider transaction that took place on Dec 30 ’24, was worth 148,504. Before that another transaction happened on Oct 01 ’24, when Company’s Director sold 10,000 for $10.11, making the entire transaction worth $101,052. This insider now owns 11,286 shares in total.
Regenxbio Inc (RGNX) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.44 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 21.49% per share during the next fiscal year.
Regenxbio Inc (NASDAQ: RGNX) Trading Performance Indicators
Check out the current performance indicators for Regenxbio Inc (RGNX). In the past quarter, the stock posted a quick ratio of 3.05. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.53.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.03, a number that is poised to hit -1.14 in the next quarter and is forecasted to reach -0.64 in one year’s time.
Technical Analysis of Regenxbio Inc (RGNX)
Let’s dig in a bit further. During the last 5-days, its volume was 0.87 million. That was inferior than the volume of 0.94 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 46.25%. Additionally, its Average True Range was 0.46.
During the past 100 days, Regenxbio Inc’s (RGNX) raw stochastic average was set at 5.91%, which indicates a significant decrease from 18.57% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 56.12% in the past 14 days, which was lower than the 74.87% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.40, while its 200-day Moving Average is $10.38. However, in the short run, Regenxbio Inc’s stock first resistance to watch stands at $6.24. Second resistance stands at $6.47. The third major resistance level sits at $6.62. If the price goes on to break the first support level at $5.87, it is likely to go to the next support level at $5.72. Assuming the price breaks the second support level, the third support level stands at $5.49.
Regenxbio Inc (NASDAQ: RGNX) Key Stats
There are currently 49,545K shares outstanding in the company with a market cap of 297.77 million. Presently, the company’s annual sales total 90,240 K according to its annual income of -263,490 K. Last quarter, the company’s sales amounted to 24,200 K and its income totaled -59,600 K.
